MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

Phase 1
Terminated
Conditions
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Recurrent B Acute Lymphoblastic Leukemia
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Refractory B Acute Lymphoblastic Leukemia
Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Interventions
Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Other: Pharmacological Study
First Posted Date
2017-04-07
Last Posted Date
2024-04-10
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
55
Registration Number
NCT03103971
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Phase 2
Completed
Conditions
Follicular Lymphoma
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma
Interventions
First Posted Date
2017-04-07
Last Posted Date
2025-01-06
Lead Sponsor
Kite, A Gilead Company
Target Recruit Count
159
Registration Number
NCT03105336
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

🇺🇸

Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 16 locations

Treatment of Adult-Onset Immunodeficiency With Bortezomib

Phase 2
Conditions
Adult-onset Immunodeficiency
Interventions
First Posted Date
2017-04-06
Last Posted Date
2017-04-06
Lead Sponsor
Mahidol University
Target Recruit Count
5
Registration Number
NCT03103555
Locations
🇹🇭

Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma

Phase 1
Conditions
B Cell Lymphoma
Interventions
First Posted Date
2017-04-05
Last Posted Date
2017-04-05
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
30
Registration Number
NCT03101709
Locations
🇨🇳

Henan Cancer Hospital, Zhengzhou, Henan, China

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1
Active, not recruiting
Conditions
Stage III Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Breast Inflammatory Carcinoma
Stage IIIA Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Metastatic Breast Carcinoma
Locally Advanced Breast Carcinoma
Stage IV Breast Cancer AJCC v6 and v7
Interventions
First Posted Date
2017-04-05
Last Posted Date
2024-12-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
43
Registration Number
NCT03101748
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

Phase 2
Recruiting
Conditions
Metastatic Thyroid Cancer
Interventions
First Posted Date
2017-04-04
Last Posted Date
2024-06-26
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
19
Registration Number
NCT03099356
Locations
🇺🇸

University of Michigan Cancer Center, Ann Arbor, Michigan, United States

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Phase 1
Withdrawn
Conditions
Plasma Cell Leukemia in Remission
Plasma Cell Myeloma
Interventions
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Procedure: pheresis
Drug: Melphalan
Biological: Palifermin
Radiation: Total Marrow Irradiation
First Posted Date
2017-04-04
Last Posted Date
2017-12-13
Lead Sponsor
City of Hope Medical Center
Registration Number
NCT03100877
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Phase 2
Completed
Conditions
Acute Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Langerhans Cell Histiocytosis
Acute Biphenotypic Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Non-Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
Therapy-Related Myelodysplastic Syndrome
Acute Myeloid Leukemia
Interventions
Biological: Anti-Thymocyte Globulin
Drug: Busulfan
Drug: Clofarabine
Drug: Cyclophosphamide
Biological: Filgrastim-sndz
Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate Mofetil
Biological: Rituximab
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Procedure: Umbilical Cord Blood Transplantation
First Posted Date
2017-03-30
Last Posted Date
2023-10-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
6
Registration Number
NCT03096782
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Phase 1
Conditions
Multiple Myeloma
Interventions
Biological: Anti-BCMA CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide
First Posted Date
2017-03-28
Last Posted Date
2019-02-27
Lead Sponsor
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
Target Recruit Count
10
Registration Number
NCT03093168
Locations
🇨🇳

Henan Province of TCM, Zhengzhou, Henan, China

CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

Phase 1
Active, not recruiting
Conditions
Prostate Cancer
Interventions
Biological: CART-PSMA-TGFβRDN cells
Drug: Cyclophosphamide
Drug: Fludarabine
First Posted Date
2017-03-24
Last Posted Date
2024-04-26
Lead Sponsor
University of Pennsylvania
Target Recruit Count
23
Registration Number
NCT03089203
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath